Friday, April 16, 2021

Positive results in first-in-U.S. trial of CRISPR-edited immune cells | Penn Today

This is GIANT news for anybody with cancer. Check this out! Finally using genetic editing to prime a patient's immune system to target individual specific cancer cells. This is super-targeted immunotherapy. This could illuminate any collateral damage from cancer treatment.

No comments:

Post a Comment

Please be constructive in your comments.